Arcus Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $247.0M | $258.0M | $117.0M | $112.0M | $383.0M |
| Research and development | $523.0M | $448.0M | $340.0M | $288.0M | $257.0M |
| Operating expenses | $633.0M | $588.0M | $457.0M | $392.0M | $329.0M |
| Operating income | -$386.0M | -$330.0M | -$340.0M | -$280.0M | $54.0M |
| Interest expense | $8.0M | $4.0M | $2.0M | $2.0M | — |
| Pretax income | -$353.0M | -$282.0M | -$301.0M | -$266.0M | $55.0M |
| Income tax expense | $0 | $1.0M | $6.0M | $1.0M | $2.0M |
| Net income | -$353.0M | -$283.0M | -$307.0M | -$267.0M | $53.0M |
| Balance Sheet | |||||
| Cash and equivalents | $222.0M | $150.0M | $127.0M | $206.0M | $148.0M |
| Current assets | $1.0B | $1.0B | $831.0M | $1.1B | $1.3B |
| Total assets | $1.1B | $1.1B | $1.1B | $1.3B | $1.6B |
| Current liabilities | $231.0M | $226.0M | $184.0M | $193.0M | $166.0M |
| Total liabilities | — | — | — | — | $750.4M |
| Total debt | $100.0M | $50.0M | $0 | — | — |
| Stockholders' equity | $631.0M | $485.0M | $462.0M | $657.0M | $842.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$482.0M | -$170.0M | -$306.0M | $438.0M | -$256.0M |
| Depreciation and amortization | $10.0M | $10.0M | $8.0M | $6.0M | $4.0M |
| Stock-based compensation | $60.0M | $76.0M | $73.0M | $65.0M | $55.0M |
| Capital expenditure | $2.0M | $6.0M | $24.0M | $6.0M | $26.0M |
| Free cash flow | -$484.0M | -$176.0M | -$330.0M | $432.0M | -$282.0M |
Shares outstanding 125.8M · Free float 62.0%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.